SVC112

SVC112 is a translation elongation inhibitor that obstructs the periodic dissociation of EF2 from the ribosome, thereby inhibiting the elongation phase of translation. It demonstrates inhibitory activity in multiple cancer cell lines, including acute myeloid leukemia (AML), multiple myeloma, colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC) . SVC112 preferentially impedes ribosomal processing of mRNA, reducing cancer stem cell (CSC) -related proteins such as Myc and Sox2. In hematological cancer cell lines, it induces apoptosis, whereas in colorectal cancer lines, the phosphorylation of c-Myc correlates with sensitivity to SVC112. The compound effectively inactivates HNSCC stem cells in vitro and prevents tumor regrowth in mouse HNSCC xenograft models. SVC112 is applicable for research on head and neck squamous cell carcinoma.